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Abstract
Development of novel therapeutic strategies to eradicate malignant tumors is of paramount importance in cancer
research. In a recent study, we have introduced a facile protocol for the preparation of corrole-protein nanoparticles
(NPs). These NPs consist of a corrole-core coated with protein. We now report that a novel lipophilic corrole, (2)Ga,
delivered as human serum albumin (HSA)-coated NPs, displayed antineoplastic activity towards human prostate
cancer DU-145 cells. Cryo-TEM analysis of these NPs revealed an average diameter of 50.2 ± 8.1 nm with a spherical
architecture exhibiting low polydispersity. In vitro cellular uptake of (2)Ga/albumin NPs was attributable to rapid
internalization of the corrole through ligand binding-dependent extracellular release and intercalation of the corrole
cargo into the lipid bilayer of the plasma membrane. This finding is in contrast with a previously reported study on
corrole-protein NPs that displayed cellular uptake via endocytosis. Investigation of the non-light-induced mechanism
of action of (2)Ga suggested the induction of necrosis through plasma membrane destabilization, impairment of
calcium homeostasis, lysosomal stress and rupture, as well as formation of reactive oxygen species (ROS). (2)Ga also
exhibited potent light-induced cytotoxicity through ROS generation. These findings demonstrate a rapid cellular
uptake of (2)Ga/protein NPs along with targeted induction of tumor cell necrosis.
Introduction
Prostate cancer is the leading cause of cancer-related
mortality in men worldwide1. Upon diagnosis, prostate
cancer is typically organ-confined or only locally
advanced2. Depending on multiple parameters including
clinical stage and prostate specific antigen (PSA) levels,
decisions are made whether to opt for active surveillance,
radiotherapy, or prostatectomy3. Once the disease has
spread outside the prostate, androgen deprivation therapy
(ADT) via chemical castration is the treatment of choice2.
Unfortunately, the response is only ephemeral and most
patients will develop resistance to ADT, progressing
towards castration-resistant prostate cancer (CRPC)
within 18 to 36 months which may be ensued by meta-
static castration-resistant prostate cancer (mCRPC)2,4.
Despite recent advances in the therapy for mCRPC, this
malignant disease remains incurable, although men suf-
fering from this disease are living considerably longer
these days2,5. Recent advances in this field of cancer
research hold great promise for ablation of calcium
homeostasis by utilizing a sarcoplasmic/endoplasmic
reticulum calcium adenosine triphosphatase (SERCA)
pump protein inhibitor in humans6.
The field of corroles, first discovered in 1964, experi-
enced little progress until 1999 when the first efficient
methodology for the synthesis of triarylcorroles was
reported7. Later, work of great importance involved the
design and synthesis of water-soluble corrole deriva-
tives8,9, which paved the way for biomedical applications.
Notably, water-soluble metal complexes were found to be
promising drug candidates for the treatment of diverse
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medical disorders, ranging from conditions where cellular
damage must be prevented (diabetes mellitus, heart, and
neurodegenerative diseases) to the eradication of malig-
nant cells10,11. The gallium(III) derivative of 5,10,15-tris
(pentafluorophenyl)-2,17-bis(sulfonic acid)-corrole, (1)
Ga, displayed potent cytotoxic effects toward cancer
cells12, particularly when conjugated with a heregulin-
modified protein that targeted the human epidermal
growth factor receptor (HER). The corrole/protein com-
plex aided in the detection of cancer cells in a nude mouse
model bearing HER+ human tumors, and it killed tumor
cells while sparing normal tissues13. In a more recent
study, a gold(III) sulfonated corrole, ((1)Au), displayed
elevated cytotoxic activity (relative to (1)Ga) toward var-
ious cancer cell lines, surpassing even cisplatin, a well-
established and widely used chemotherapeutic14.
Further investigation into the antineoplastic activity of
metallocorroles revealed that the lipophilicity of corrole
derivatives plays a central role in their activity toward
malignant cells15. This finding led to the establishment of
a facile procedure for the introduction of highly lipophilic
corroles into biological media, consisting of corrole
nanoparticles (NPs) coated with native proteins15. Inde-
pendently, we also developed a novel one-pot synthesis of
5,10,15‐tris(trifluoromethyl)corrole and its Ga(III) deri-
vative, (2)Ga (Fig. 1a), whose low molecular weight could
be beneficial for medicinal applications16,17.
Here we report the antineoplastic activity of human
serum albumin (HSA)-coated NPs of (2)Ga in the treat-
ment of prostate cancer cells, particularly the well-
documented androgen-independent DU-145 cell line,
which displays moderate to high metastatic potential18,19.
We observed fast cellular uptake and release of (2)Ga
cargo from (2)Ga/HSA NPs into DU-145 cells in an
extracellular, ligand binding-dependent manner. (2)Ga
was found to induce necrosis by disrupting calcium
homeostasis and by increasing the level of reactive oxygen
species (ROS), and both proceeded more rapidly upon
photoactivation. Importantly, our findings open the way
for preclinical evaluation of these NPs as therapeutic
agents against prostate cancer.
Results
The formation of (2)Ga/HSA NPs was confirmed by
utilizing our previously established protocols15. HPLC
analysis (Fig. 1b–d) uncovered trends reminiscent of the
reported NPs formed by 5,10,15-tris(pentafluorophenyl)
corrole (TPFC) and its metal complexes. Analysis by size-
exclusion chromatography revealed a fraction with an
average retention time of 17min, indicative of the for-
mation of much larger particles than the later eluting
albumin (Fig. 1b, c). In the HPLC-injected sample, (2)Ga
is roughly equally distributed between the particle fraction
at 17 min and the monomeric fraction at 29 min (Fig. 1b,
c). UV-vis examination of the eluted fractions (Fig. 1d)
supports this conclusion; the Soret band of protein-coated
NPs is very broad (note also the λmax= 280 nm due to
HSA), while it is very sharp in the fraction eluting toge-
ther with monomeric albumin. Assessment of particle size
by the Nanosight NS300 system (Fig. S1) indicated a mean
NP size of 69.2 ± 0.2 nm. Cryo-TEM analysis of (2)Ga/
HSA NPs revealed the formation of particles that were
morphologically distinct from tpfc-based NPs15. Particles
were spherical with an average diameter of 50.2 ± 8.1 nm
(Fig. 1e, f). Relative to tpfc-based NPs (1̴00 nm), (2)Ga
formed smaller, more compact particles with lower
polydispersity (Fig. S1).
The cytotoxic activity of (2)Ga/HSA NPs (Fig. 2a) over a
range of concentrations was first assessed against six
cancer cell lines from the NCI-60 panel (Fig. 2b). IC50
values ranged from 2–83 µM after 24 h incubation to
2–4 µM after 48 h incubation, with greater cytotoxicity
against MDA-MB-231 and HCT-116 cell lines upon 48 h
exposure. The experiments were initially performed in the
dark to minimize cytotoxicity due to corrole photo-
excitation10. The initial assessment of (2)Ga/HSA NPs
indicated that the DU-145 cell line responded more
rapidly when compared to other cell lines upon treatment
(plasma membrane blebbing and cell death were clearly
visible by light microscopy within a few minutes). Since
plasma membrane blebbing is considered a hallmark of
apoptosis, we have used the Annexin V-FITC assay to
detect apoptosis. Examination of DU-145 cells upon 4 h
and 24 h incubation with (2)Ga/HSA NPs using this
Annexin V-FITC apoptosis assay along with flow cyto-
metry, confirmed the induction of cell death with IC50
values consistent with those obtained with crystal violet
staining analysis (Fig. 2c, d, S2). After 4 h of incubation
with (2)Ga/HSA NPs, there was a dose-dependent
increase in the percentage of Annexin V-FITC fluor-
escent tumor cells, thus attaining 40% apoptotic cells at
15 µM NPs (Fig. 2c, d). Moreover, co-staining with pro-
pidium iodide (PI) showed cell death, attaining up to 85%
dead cells upon 4 h treatment with 10 µM NPs, of which
~30% were positive for Annexin V-FITC, indicating late
stage apoptosis or necrosis (Fig. 3a, b). Hence, a sub-
stantial component of cell death, apparently via necrosis,
did not involve phosphatidylserine inversion. These
results suggest that our NPs inflict a rapid tumor cell
death predominantly via necrosis.
Mitochondrial depolarization, an established apoptotic/
necrotic marker, was markedly detectable after 4 h of
treatment with 10, 15, and 20 µM of (2)Ga/HSA NPs (Fig.
3c, panels e–g; Fig. 3d). Live microscopy imaging of the
uptake of (2)Ga/HSA NPs by DU-145 cells employing
MitoTracker green (MTG) staining after 4 h of incubation
revealed both cell uptake of (2)Ga and mitochondrial
depolarization, as MTG labels only actively respiring
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mitochondria (Fig. 3e, panels a, c). In cells exhibiting a
positive mitochondrial MTG signal, i.e., those treated
with 5 µM (2)Ga, co-localization of (2)Ga and MTG
was clearly evidenced as yellow fluorescence (Fig. 3e,
panel b). (2)Ga-treated cells apparently displayed apop-
totic bodies and possibly plasma membrane blebbing
visible by DIC microscopy, suggesting that some minor
component of cell death presumably occurred via late
apoptosis (Fig. 3e, panels b, c) on top of the predominant
necrosis as shown below; moreover, cells treated with
20 µM (2)Ga formed large vesicular bodies (Fig. 3e, panel
c). These results are consistent with our abovementioned
observations indicating a rapid induction of cell death by
(2)Ga/HSA NPs in prostate cancer DU-145 cells, even
within minutes.
To characterize the molecular mechanism underlying
the cell death induced by (2)Ga/HSA NPs, we have con-
ducted experiments with the established pan-caspase
inhibitor Z-VAD-FMK, as well as the RIP1 kinase
(RIPK-1) inhibitor Necrostatin-1, which block apoptosis
and necroptosis, respectively. Western blot analysis of
both PARP cleavage and pro-caspase-3 activation by
proteolytic cleavage, revealed intriguing results (Fig. 3f).
(2)Ga/HSA NPs induced PARP cleavage and yielded a
74 kDa fragment which was slightly inhibited by Z-VAD-
FMK but not with Necrostatin-1 (Fig. 3f, lanes 6, 9, 12). It
should be noted that the 74 kDa PARP fragment is a
hallmark of PARP cleavage by lysosomal cathepsin pro-
teases released during necrosis20,21. Therefore, the slight
inhibition of PARP cleavage to the 74 kDa fragment by
Fig. 1 Characterization of protein-coated corrole nanoparticles. a Molecular structure of 5,10,15-tris(trifluoromethyl)corrole and its gallium(III)
complex, (2)Ga. b HPLC chromatogram (Sephadex TM 200 10/300 GL column) for the detection of (b) HSA (only) and (c) HSA with (2)Ga in HSA/
corrole NPs. HSA was detected at 280 nm (blue line) and corrole was detected at 422 nm (red line). d UV-Vis spectra recorded for HPLC-injected (2)
Ga/HSA NPs at different retention times. e Representative Cryo-TEM imaging of (2)Ga/HSA NPs and (f) the size distribution of imaged particles.
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Z-VAD-FMK could be explained by the non-specific
activity of this inhibitor and its ability to also inhibit
cathepsins B and H22,23. In contrast, 5 µM Camptothecin
(CPT; Fig. 3f lanes 7, 10, 13), a cytotoxic antitumor agent
which blocks topoisomerase I and induces apoptosis,
brought about PARP cleavage and yielded the expected
89 kDa fragment—a hallmark of apoptosis. Expectedly,
CPT-induced PARP cleavage was inhibited by Z-VAD-
FMK, but not by Necrostatin-1 (Fig. 3f, lanes 10, 13).
Surprisingly however, cleaved caspase-3 was not observed
in CPT-treated cells (Fig. 3f, lanes 7, 10, 13). A potential
explanation for this latter result is that the active form of
caspase-3 is rapidly turned over, when compared to the
pro-caspase-3 form in cancer cells24, making it difficult to
observe the cleaved caspase-3, more so after the 20 h
incubation period with CPT and (2)Ga/HSA NPs. In
contrast, a dose-dependent increase in cleaved caspase-3
(Fig. 3f, 12 kDa and 17 kDa, lanes 4–6) could be detected
after 20 h exposure to (2)Ga/HSA NPs. The NPs-induced
cleavage of pro-caspase-3 was not inhibited by Z-VAD-
FMK, but was blocked by Necrostatin-1 (Fig. 3f, lanes 9,
12). This indicates the role of the RIPK-1 pathway and
caspase-8 in the observed activation of caspase-325. Taken
collectively, the apparently predominant mechanism of
cell death induced by (2)Ga/HSA NPs largely proceeds via
necrosis, accompanied by hallmarks of lysosomal mem-
brane permeabilization and release of lysosomal cathepsin
proteases. Future studies are warranted to reveal the
hierarchy of the different pathways and their inter-
connection in the induction of this necrotic cell death.
The fast dynamics of cell death induction prompted us
to assess cellular calcium flux as a potentiating factor in
the (2)Ga cytotoxic mechanism. Monitoring intracellular
calcium levels was performed using a calcium fluorescent
indicator (Fluo-8 AM) and live time-lapse imaging in DU-
145 cells (Fig. 4, Videos 1–3). Upon the addition of 20 µM
(2)Ga/HSA NPs, a prominent sustained increase in
cytosolic calcium content was observed 90 s after
administration (Fig. 4b, d, panel b, Video 2). The intensity
of fluorescence remained strong throughout the obser-
vation period, indicating elevated calcium release from
intracellular compartments and/or influx from the
extracellular milieu. The addition of 2 µM (2)Ga/HSA
NPs led to similar results, but with a lower intracellular
calcium signal. A minor elevation in the fluorescence from
the detector was observed, between 7 and 10min (Fig. 4a,
d, panel a, Video 1). In contrast, no change in cellular
calcium levels was observed in control cells incubated with
HSA (Fig. 4c, Video 3). Repeating the assay with 2 µM (2)
Ga/HSA in DU-145 cells with photoexcitation 30 s after
NP addition, induced substantial elevation of intracellular
calcium levels (Fig. S3a, Video S1). A single light pulse was
sufficient to induce calcium levels comparable to that
observed with 20 µM NPs under dark conditions, even
with 10-fold lower NP concentration.
Calcium and ROS figure prominently as intracellular
signaling molecules in regulating a multitude of cellular
functions26. Since calcium and ROS display cross-talk
between the cytosol and mitochondrial matrix, an
experiment was designed to determine whether or not (2)
Ga induces ROS production followed by intracellular
calcium increase or vice versa.
The addition of CellROX green, a fluorescent ROS probe,
revealed a strong elevation in cellular ROS levels after only
4min following addition of (2)Ga/HSA NPs (20 µM;
Fig. 4e, f). Since an intracellular calcium increase was
observed 90 s after addition of (2)Ga/HSA NPs (vide
supra), it could have caused the induction of ROS26. The
rapid intracellular calcium increase suggested the induction
of phospholipid plasma membrane instability potentially
involving nanopore disruption or formation of unstable
regions in the bilayer. In accord with previous results,
electronic excitation of (2)Ga in cells yielded much faster
dynamics (less than 3min) of ROS generation (Fig. S5,
Video S4), while drug-free control cells did not (Video S5).
To determine the extent of (2)Ga/HSA NPs localization
within lysosomes, DU-145 cells were labeled with Lyso-
Tracker green (LTG), a lysosome-specific fluorescent dye.
Within 10min of treatment with (2)Ga/HSA NPs, the
fluorescence was dramatically attenuated, implying the
disruption of lysosomal structure (Fig. 5a, video 5, 6). This
finding indicated destabilization of the outer cellular
membrane leaflet and concomitant elevation of intracel-
lular calcium levels. We conclude that membrane per-
meabilization/disruption must be exhibited by other
cellular organelles. By following the uptake dynamics of
(2)Ga/HSA NPs by DU-145 cells with time-lapse micro-
scopy, fluorescence could be detected on the cell surfaces
(see figure on previous page)
Fig. 2 Cytotoxic and apoptotic effects of (2)Ga/HSA NPs in prostate cancer cells. a Size, particle concentration, corrole/protein ratios, and
content parameters of (2)Ga/HSA NPs used in cytotoxicity assay. b Dose-response curves and IC50 values for a 48 and 72 h exposure (a and b,
respectively) of human tumor cell lines to (2)Ga/HSA NPs were evaluated by a crystal violet staining assay. Data represent the mean ± SEM of two
independent experiments. c AnnexinV-FITC staining of DU-145 cells incubated for 4 h with (a) HSA control and (2)Ga/HSA NPs at the following
concentrations (b) 2 µM, (c) 5 µM, (d) 10 µM, (e) 15 µM, and (f) 20 µM. d Plotting of the gated cells (within M1) that are positive to AnnexinV-FITC
(i.e., apoptotic cells) vs. (2)Ga concentration and determination of the IC50 value (IC50= 6.85 µM); data points represent the means ± SEM (n= 3),
*p < 0.001 vs. control untreated cells.
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within the first few seconds (Fig. 5b, Video 7). Within 1 to
2min of incubation, (2)Ga could be detected within cells,
implying fast uptake dynamics with initial binding to the
plasma membrane. On the other hand, no uptake of (2)
H3/HSA NPs (the free base form of (2)Ga with the same
quantum yield of fluorescence16, i.e., a comparable
structural analog, Fig. 1a) could be detected within the
time frame employed in the (2)Ga/HSA NPs imaging
experiments (Fig. S6, Videos S6). Even after 1 h of incu-
bation with (2)H3/HSA NPs, only several cells began to
display a fluorescence signal in their plasma membrane
from the fluorescent (2)H3 corrole (Fig. S7, Video S7),
thereby indicating that the metal bound within the corrole
macrocycle plays a role in corrole/HSA NPs uptake
dynamics. The poor uptake of (2)H3 by DU-145 cells may
account for the lack of changes in intracellular basal levels
of calcium in cells treated with 20 µM (2)H3/HSA NPs
(Fig. S3b, c, Video S2, S3). This is accentuated by the
inability to obtain IC50 values for the (2)H3/HSA NPs in
DU-145 cells after 24 h of incubation in dark conditions
(Fig. S4). To address the possibility that these phenomena
were solely due to monomeric corrole bound to HSA or
vice versa (i.e., only due to the corrole NPs), we conducted
an uptake experiment with virtually identical concentra-
tions of isolated NPs and with albumin bound monomeric
corrole isolated from the surfactant of NPs samples after
centrifugation (×3 centrifugation isolation protocol). Both
the isolated NPs and the monomeric albumin bound
corroles (corresponding to peaks eluting at 17 and 29 min
in Fig. 1) displayed uptake reminiscent of the non-
separated formulation (i.e., initial membrane binding
followed by fast partitioning into the cells) (Video 8, 9).
We suggest that both monomeric bound corrole and
corrole NPs display the same mechanism of uptake fol-
lowed by induction of necrosis.
To elucidate the role of HSA in cellular uptake of (2)Ga,
the following questions were addressed: a) how crucial is
plasma membrane binding for the uptake of (2)Ga/HSA
NPs; and b) what is the role of HSA in the process of
cellular internalization of (2)Ga (Fig. 6)? We first assessed
the likelihood of simple diffusion through the plasma
membrane, despite the fact that passive diffusion of (2)Ga
is an unlikely mode of internalization considering the
extremely slow diffusion rates of (2)Ga/HSA NPs dis-
solved in PBS into toluene or dichloromethane (DCM)
(Fig. 6a, Fig. S8). As previously reported with other cor-
roles15, extraction into DCM or toluene was not observed
even upon vigorous stirring or shaking of the NPs in the
PBS/DCM mixture (Video 10). Next, the uptake of (2)Ga/
HSA NPs in regular media was examined by preparing
NPs coated with HSA covalently modified with FITC
(HSA-FITC). Upon incubation of DU-145 cells with (2)
Ga/HSA-FITC NPs (20 µM), intracellular (2)Ga fluores-
cence could be detected within 5 min of incubation, while
green fluorescence from FITC tagged HSA appeared after
15 min (Fig. 6b, Video 11- HSA-FITC, Video 12- (2)Ga).
We conclude that (2)Ga/HSA NPs released their metal-
locorrole cargo upon extracellular binding to the plasma
membrane. We considered the possibility that this result
could have been due to exchange of HSA-FITC-NPs with
non-fluorescent albumin from the media; however, upon
repeating the experiment in serum free media, we
obtained virtually identical results (Video S8- HSA-FITC
channel, Video S9- (2)Ga channel).
(see figure on previous page)
Fig. 3 Detection of (2)Ga/HSA NPs uptake, cell death and disruption of mitochondrial membrane potential in prostate cancer cells.
a AnnexinV-FITC staining of DU-145 cells incubated for 4 h with (a) HSA control and (2)Ga/HSA NPs at the following concentrations: (b) 2 µM, (c)
5 µM, (d) 10 µM, (e) 15 µM and (f) 20 µM. Propidium iodide (PI) was used as a nuclear counterstain to discriminate necrotic/dead cells. Panel 1 (Aa)
represents the percentage of live cells (negative for both AnnexinV-FITC and PI). Panel 2 represents necrotic cells (PI positive). Panels 3 (AnnexinV-FITC
positive) and 4 (AnnexinV-FITC and PI positive) represent early and late apoptotic/necrotic cells, respectively. b Summary of data sets depicting the
percentage of tumor cell that were positively stained for necrosis (i.e., solely PI positive) under the same gating conditions from three distinct
experiments; data points represent the means ± SEM (n= 3), *p < 0.001 vs. control untreated cells. c Flow cytometric analysis of DU-145 cells treated
with a mitochondrial depolarization reporter kit (MitoProbeTM DiOC2(3)) after 4 h of incubation with: (a) HSA control; (b) CCCP, a protonophore and
an uncoupling agent that blocks oxidative phosphorylation (positive control); and (c–g) (2)Ga/HSA NPs at 2, 5, 10, 15, and 20 µM, respectively. Note
the red arrow pointing towards the left panel indicating the percentage of mitochondrial depolarization (obtained from CCCP-treated cells).
d Summary of data sets depicting the percentage of tumor cells which stained positive for early mitochondrial depolarization (i.e., lower FITC
fluorescence) under the same gating conditions from three distinct experiments; data points represent the means ± SEM (n= 3), *p < 0.001 vs.
control untreated cells. e Uptake of (2)Ga/HSA NPs by DU-145 prostate cancer cells after 4 h of incubation with: (a) HSA control + 30 min incubation
(added to the wells just before imaging) with 200 nM MitoTracker green (MTG) followed by three washes; (2)Ga/HSA NPs at: (b) 5 µM, (c) 20 µM +
30 min incubation with 200 nM MTG and triple washes. Shown are superimposed images of conditions specific for detection of MTG (green
fluorescence), (2)Ga (red fluorescence), and phase contrast images of the same field. Fluorescence was recorded using a ×20 objective and a LSM700
confocal microscope supported with Zen software. Samples were excited at 488 nm (3%) for MTG; and at 405 nm (10%) for (2)Ga detection.
Representative images of 12 separate fields. White arrows point at possibly apoptotic cells (i.e., those displaying plasma membrane blebbing).
f Western blot analysis of proteins isolated from cells pre-treated for 3 h with vehicle control, 50 µM of Z-VAD-FMK or Necrostatin-1. Following
pretreatment, cells were incubated for 20 h with (2)Ga/HSA NP (NPs; 5, 10, 15, or 20 µM), NPs (15 µM), or camptothecin (CPT; 5 µM) without the
removal of inhibitors. Band intensities were quantified using ImageLab software (Bio-rad) relative to vehicle control in lane 1. Representative results of
two experiments are shown.
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To further describe the interaction of (2)Ga/HSA NPs
with the plasma membrane, we used the Langmuir iso-
therm equation (Fig. S9) to determine the dissociation
constant associated with (2)Ga/HSA NP-binding to DU-
145 cells. Employing flow cytometry, we plotted (2)Ga
emission maxima from cells incubated at 4 oC with var-
ious concentrations of NPs (Fig. S9). From the fitted
Langmuir plot, Kd is ~9 µM (Fig. S9). To confirm that the
NPs remain bound to the cell surface, and that the cargo
was not internalized into cells at 4oC, the experiments
were repeated using an Amnis ImageStream®X Mark II
apparatus for cell imaging during flow cytometry analysis.
Fluorescence corresponding to the outer cell surface
could be detected, but there was no fluorescent signal
from the intracellular compartment (Fig. S10c). From the
Langmuir plots, the estimated Kd using the Amnis system
is ~7 µM (Fig. S10a, b). Since NP binding to the plasma
membrane is in accord with the Langmuir model,
including binding-site saturation, we suggest that there is
specific binding to the cell surface. A simple competitive
binding experiment was performed to validate this
hypothesis: in this experiment, we added HSA to cells
incubated in serum-free medium prior to adding (2)Ga/
HSA NPs (20 µM) (Fig. 6c). Images obtained by confocal
microscopy showed that cells incubated in serum-free
medium displayed substantially stronger fluorescence
from (2)Ga relative to cells in medium containing 10%
serum (Fig. 6c, d), a finding that could be attributed to NP
binding by albumin, as fetal calf serum contains sub-
stantial amounts of the protein. Cells that were incubated
with excess HSA (16mg/mL) in serum-free medium did
not display uptake of (2)Ga after 10 min incubation
(Fig. 6c, d), indicating that initial NP binding to the cell
surface is essential for translocation of (2)Ga from an NP
into the plasma membrane, which in turn is consistent
with slow release rates of metallocorroles from NPs into
organic phases (Fig. 6a, S8).
To examine the potential role of endocytosis in (2)Ga
uptake by DU-145 cells, the effect of well-established
pharmacological inhibitors of both clathrin-mediated and
caveolae-dependent endocytosis on NP uptake was
determined. In particular, one clathrin inhibitor
(chlorpromazine) has been shown specifically to inhibit
albumin endocytosis27–33. Incubation of cells with both
clathrin-mediated and caveolae-mediated endocytosis
inhibitors for 30min prior to addition of (2)Ga/HSA NPs
was revealing: instead of inhibiting NP uptake, enhanced
cellular uptake of (2)Ga was observed by confocal
microscopy (Fig. 7). Chloroquine, chlorpromazine (cla-
thrin-mediated endocytosis inhibitors), and nystatin
(Caveolae-mediated endocytosis inhibitor), displayed
substantial increases in cellular uptake of (2)Ga, whereas a
more modest effect was found for indomethacin (caveo-
lae-mediated inhibitor) (Fig. 7b). This surprising result
could mean that there is reduced downregulation of
extracellular target receptors, thereby increasing binding
of (2)Ga/HSA NPs, which in turn would enhance uptake
of (2)Ga by treated cells. The prominent difference
between indomethacin and the other inhibitors could be
explained in this way. Indomethacin does not only inhibit
caveolae-mediated endocytosis, it also inhibits plasma-
lemmal vesicles from returning to the cell surface30, so the
effect of overexpression of extracellular receptors (by
blocking downregulation) would be mitigated by reduced
fusion of plasmalemmal vesicles with the plasma
membrane.
Discussion
On the 29th of December 1959, the Nobel Laureate
Richard P. Feynman gave a famous talk entitled “There’s
Plenty of Room at the Bottom” at the Annual Meeting of
the American Physical Society34. Extrapolating from
known laws of physics; he envisioned a future dominated
by the design and construction of nano-objects, atom by
atom, molecule by molecule. If Feynman were alive today,
he would say that NPs for drug delivery are prominent
examples of the tiny objects he had in mind. Formulation
of albumin-based NPs as controlled-release drug delivery
systems, using advanced nanotechnology techniques such
as desolvation, emulsification, thermal gelation, nano-
spray drying, nab-technology, and self-assembly, has been
widely investigated35–41. Examination of the literature
reveals that the vast majority of NP formulations involve
covalent or quaternary structural modifications of the
(see figure on previous page)
Fig. 4 Kinetic study of cellular calcium flux and formation of ROS by (2)Ga/HSA NPs. Time-lapse fluorescence microscopy imaging of DU-145
cells (series ranging from time points t= 0, 3, 6, and 10 min) incubated with the calcium indicator Fluo-8 AM (4 µM) for 30 min prior to triple washes
and the addition of: (a) 2 µM (2)Ga/HSA NPs, (b) 20 µM of (2)Ga/HSA NPs, and (c) HSA control; (d) quantification of fluorescence emitted from each
cell in 12 fields obtained from 2 µM (a) and 20 µM (b) of (2)Ga/HSA NPs. Data represent the mean ± SEM (n= 6). (e) Time-lapse microscopy imaging
of live DU-145 cells (series ranging from time points t= 0, 3, 6, 9, 12, and 15 min) incubated with 10 µM of the ROS indicator CellROX green
(accumulated mainly in the nucleus) for 30 min prior to triple washes and the addition of 20 µM of (2)Ga/HSA NPs- series of images taken at time
intervals of 1 min ranging from t= 0 (upper left corner) to t= 15 min (lower right corner); time points are indicated in white on the upper left corner
of each image; (f) quantification of fluorescence from the center of each cell nucleus in 12 different fields; data points are presented as mean ± SEM
(n= 6). Fluorescence was recorded using a ×20 objective and an IN Cell analyzer 2000 software (GE Healthcare). Samples were excited using a FITC
filter for Fluo-8 AM or CellROX green detection. Images of 12 separate fields were obtained from 3 independent experiments.
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Fig. 5 (See legend on next page.)
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albumin macromolecule. In contrast, we have developed a
very efficient NP fabrication procedure in which lipophilic
corroles and non-modified albumin assemble sponta-
neously15. In the current investigation, we employed our
reproducible protocol to construct NPs containing the newly
introduced (2)Ga, which, as it is much smaller than most
corroles, likely would form smaller NPs with enhanced
bioavailability (in accord with Lipinski’s rule of five)42.
Indeed, we found that both the distribution of (2)Ga between
monomeric HSA and NPs, as well as NP architecture were
unlike other conjugated-particle properties. The (2)Ga/HSA
NPs displayed remarkable homogeneity, with sizes ranging
between 50–80 nm, well within the range (30–100 nm) that
would allow accumulation in solid tumors43.
With a reproducible formulation in hand, the cyto-
toxicity of (2)Ga NPs was first tested by determining IC50
values in 6 different tumor cell lines. DU-145 was selected
for in-depth investigations for the following reasons: (a)
fast induction of cell death by (2)Ga in this cell line; (b) its
relatively high metastatic potential18,19; (c) elevated levels
of SPARC expression, the protein responsible for
increased albumin uptake in metastatic prostate cancer
cells44,45; and (d) its potential role as a preclinical in vitro
model for mCRPC46.
The fast cellular uptake of (2)Ga appears to occur via
facilitated diffusion, rather than through relatively slow
endocytosis documented for NPs containing larger cor-
roles15. Cumulative evidence suggests that (2)Ga/HSA
NPs bind to a putative receptor on cell surfaces (Kd
~9 µM), thereby facilitating corrole redistribution from
compact NPs into the plasma membrane. Blocking NP
binding to the cell surface by excess serum albumin was
sufficient to stop (2)Ga entry into DU-145 cells. Random
diffusion of corrole from NPs into a lipid bilayer likely
could not occur, owing to extremely slow release rates of
(2)Ga into organic solvents. Surprisingly, (2)H3, in the
form of (2)H3/HSA NPs, was not taken up by DU-145
membranes under virtually identical experimental con-
ditions. We are puzzled by this different behavior, but we
note that the poor uptake accords with the lack of cyto-
toxicity and impairment of calcium homeostasis displayed
by (2)H3/HSA NPs. Inhibition of endocytosis by
established inhibitors led to enhanced accumulation of (2)
Ga, a finding that could be attributable to poor inter-
nalization of cell-surface-NP-bound receptors, which in
turn would lead to an excess of receptors on the cell
surface. These receptors would bind new NPs after dis-
assembly of previously bound particles47.
The mechanism of action of (2)Ga under dark (light-
free) conditions indicates impairment of calcium home-
ostasis, lysosomal stress, and eventually ROS formation,
thereby inducing necrosis. This outcome is reflected in
the fast kinetics (increased fluorescence) of the calcium
probe Fluo-8 and the much slower kinetics of the ROS
reporter CellROX green. The elevation of cytosolic cal-
cium levels may induce production of ROS, which is likely
mediated by cytosolic ROS-generating enzymatic sites
(NADPH-oxidase, peroxisomes, cytochrome P450, xan-
thine oxidase, cyclooxygenase, and lipoxygenase)26. It also
may stimulate ROS production via inhibition of mito-
chondrial electron transport26. The formation of large
vesicular bodies containing (2)Ga (indicated by red
fluorescence of imaged cells) and the loss of lysosomes
inferred from the loss of LTG fluorescence may imply
lysosomal stress, lysosomal membrane permeabilization
and lysis as a necrosis mechanism; furthermore, the
release of lysosomal cathepsin proteases (a necrosis hall-
mark) is due to loss of lysosomal membrane integrity and
possible lysosome rupture. Further studies are warranted
to delineate the pathways activated by (2)Ga, leading to
this apparent necrotic cell death. The reason for calcium
homeostasis impairment remains a mystery. Our initial
results suggest that the focus should be on validating
whether or not (2)Ga increases the fluidity of cellular
membranes as recently shown for certain lipophilic
compounds48. Cancer cells tend to exhibit a high density
of saturated fatty acid-based phospholipids, rendering
their membranes more rigid and much less fluid49,50: it
follows that increasing membrane fluidity by (2)Ga may
lead to altered transmembrane protein activity and sig-
naling, which would be accompanied by uncontrolled
calcium diffusion. Further research should shed light on
the interaction of (2)Ga with cell membranes and its role
in inducing cell death.
(see figure on previous page)
Fig. 5 Kinetic of cellular internalization of (2)Ga/HSA NPs and disruption of lysosome in prostate cancer cells. a DU-145 cells: (a) after 30 min
incubation with LysoTracker green (LTG) (150 nM); (b) same field after consecutive 10 min incubation with (2)Ga NPs (20 µM). Images were taken
using conditions for specific detection of LTG (green fluorescence), (2)Ga (red fluorescence) and phase contrast images of the same field.
Fluorescence was recorded at ×20 magnification using a LSM700 confocal microscope and Zen software. Samples were excited at 488 nm (3%) for
LTG and at 405 nm (10%) for (2)Ga detection. Representative images of 12 separate fields and representative results of 3 independent experiments
are shown. b Time-lapse microscopy imaging of (2)Ga/HSA NPs uptake in DU-145 cells: series of images taken at time intervals of 30 s ranging from
t= 0 (upper left corner) to t= 6.5 min (lower right corner). The time point is indicated in white on the upper left corner of each image; (c)
quantification of fluorescence from the center of each cell in 12 separate fields. Data points are presented as mean ± SEM (n= 6). Fluorescence was
recorded using a ×20 objective and an IN Cell analyzer 2000 software (GE Healthcare). Samples were excited using a CFP filter for (2)Ga detection.
Representative images of 12 separate fields and representative results of 3 distinct repeats are presented.
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Fig. 6 Characterization of the interaction of (2)Ga/HSA NPs with the plasma membrane of DU145 cells. a Table summarizing the binding
affinity of (2)Ga/HSA NPs to DU-145 cells and (2)Ga diffusion rates from NPs into an organic phase. b Uptake dynamics of (2)Ga/HSA-FITC NPs (20 µM)
measured by confocal imaging at time points of 5–30 min at 5 min intervals in the same treated well. c Uptake dynamics after incubation for 10 min
with (2)Ga/HSA NPs (20 µM) followed by confocal microscopy imaging in the wells containing medium supplemented with 10% fetal calf serum,
serum-free medium, and serum-free medium supplemented with 16 mg/mL HSA. d Quantification of fluorescence levels in each treatment group
determined from 12 separate fields. Points are mean ± SEM (n= 3), *p < 0.01. Shown are images of the conditions specific for the detection of HSA-
FITC (green fluorescence), (2)Ga (red fluorescence), and phase contrast images of the same field. Fluorescence was recorded at ×10 magnification for
(b) and ×20 magnification for (c) using a LSM700 confocal microscope and Zen software. Samples were excited at 488 nm (2%) for HSA; and at
405 nm (10%) for (2)Ga detection. Representative images of 12 independently derived photos obtained from 3 independent experiments.
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In 2016, Wilhelm and coworkers published a metadata
survey of the NP-drug delivery literature51. This review
revealed that NPs have made little impact in the field of
nanomedicine. In the best cases in cancer therapy, for
example, tumor accumulation did not exceed 10%.
Given that an NP would need to undergo active endo-
cytosis into malignant cells to release its drug cargo, it is
not surprising that even approved (non-targeted) nano-
medicines such as Abraxane and Doxil are not very
effective52–54; indeed, their approval is rather due to
improved toxicological profiles (not improved ther-
apeutic activity)55. Although NP accumulation in
malignant tumors is low, investigations of their uptake
kinetics, drug loading and mode of drug release likely
will greatly influence therapeutic profiles. The extra-
cellular, binding-dependent, fast release of (2)Ga/HSA
NPs may prove to be of importance in understanding
drug release dynamics and its impact in nanomedicine.
Furthermore, our finding of rapid induction of necrotic




EMEM growth medium, fetal bovine serum, penicillin-
streptomycin, and supplements were purchased from
Biological Industries (Beit-Haémek, Israel). MitoTracker
Green (MTG), LysoTracker green (LTG), and ER-tracker
green (ETG) were obtained from Life Technologies,
Rhenium (Jerusalem, Israel). Z-VAD-FMK (#S7023) and
necrostatin-1 (#S8037) were purchased from Selleck
Chemicals (Houston, TX). The materials used for synth-
esis and work-up procedures were purchased from Sigma
Aldrich, Merck, Fluka, and Frutarom and used as received
unless otherwise stated. Deuterated solvents (Sigma
Aldrich isotopes products) with a 99.5% minimum deu-
teration were used as received. Silica gel for column
chromatography (Silica Gel 60, 63–200 µm mesh) was
obtained from E. Merck Ltd. Pyrrole was run through a
short basic alumina column and aldehydes were purified
by vacuum distillation before use. Anti-caspase-3 poly-
clonal (CST#9662), polyclonal anti-PARP (CST#9542),
and anti-β-actin monoclonal (CST#4970) antibodies were
Fig. 7 Effect of pharmacological endocytosis inhibitors on the uptake of (2)Ga/HSA NPs by DU-145 cells. a DU-145 cells were pre-incubated
with: (a) vehicle, (b) chlorpromazine (20 µM), (c) nystatin (30 µM), (d) chloroquine (100 µM), and (e) indomethacin (300 µM) for 30 min; followed by cell
incubation with (2)Ga/HSA NPs (20 µM) for 1 h and assessed by live confocal microscopy. Fluorescence was recorded at ×20 magnification using a
LSM700 confocal microscope and Zen software. Samples were excited at 405 nm (10%) for (2)Ga detection. Representative images of 12 separate
fields are presented. Shown are superimposed images with conditions specific for detection of (2)Ga (red fluorescence) and DIC images of the same
fields; (b) quantification of fluorescence from each treated group measured from 12 separate fields. Points are shown as mean ± SEM (n= 3),
*p < 0.001, #p < 0.05. Results were obtained from 3 independent experiments.
Soll et al. Cell Death Discovery            (2020) 6:67 Page 13 of 17
Official journal of the Cell Death Differentiation Association
purchased from Cell Signaling Technology (Danvers, MA).
Anti-Cleaved Caspase-3 monoclonal antibody (#ab32042)
and anti-rabbit IgG H&L HRP-conjugated (#ab6721)
antibodies were from Abcam (Cambridge, MA).
Synthetic procedures
(2)Ga used for human serum albumin coated NPs was
prepared using a previously reported procedure16.
Formulation of albumin/corrole nanoparticles
A solution of 400 µL of 1 mM corrole dissolved in
DMSO was added dropwise (0.04 mL/min) to a 3.6 mL of
100 µM BSA or HSA in PBS, pH 7.2, and stirred at
500 rpm in a 5 °C water bath. Solutions were incubated for
30min at 5 °C and transferred to dialysis tubing for 24 h
dialysis in a 1 L PBS solution. Dialysis tubes were pur-
chased from Spectrum labs, cat. No. 3787-D20; type: RC;
MWCO: 12-14000. Dialysis tubing was treated vigorously
with EDTA: tubing was immersed in 1 L of 2% sodium
bicarbonate/1 mM EDTA solution in a 2 L glass beaker.
Tubing was rinsed thoroughly with ddH2O (sterile ultra-
pure water) and submerged completely in 50% ethanol/
1 mM EDTA and stored at 4 °C. Tubing was rinsed
thoroughly before use.
DLS and nanosight NS300 systems
Samples of NPs were diluted 10,000-fold in PBS. They
were then measured using the Nanosight NS300 or the
PSS Nicomp 380 DLS-ZLS Analyzer in accordance with
the manufacturer’s instructions.
1.3.5 Cryo-TEM analysis
Samples of NPs were prepared to be at a mass percentage
of 1% particles in PBS and the Cryo-TEM specimens were
prepared in a controlled environment vitrification system
(CEVS). Cryogenic transmission electron microscopy
(Cryo-TEM) imaging was performed using a FEI Talos
200C, FEG-equipped Cryo-dedicated high-resolution
transmission electron microscope (TEM and STEM),
operated at an accelerating voltage of 120 kV. Specimens
were transferred into an Oxford CT-3500 Cryo-holder
(Philips) or a Gatan 626DH (FEI) Cryo-holder, and equi-
librated below −178 °C. Specimens were examined using a
low-dose imaging procedure to minimize electron-beam
radiation damage. Images were recorded digitally by a
Gatan Multiscan 791 cooled CCD camera (Philips CM
120), or a Gatan US 1000 high-resolution CCD camera
(Tecnai T12 G2), using DigitalMicrograph software.
HPLC
HPLC analysis was performed using a MERCK HITA-
CHI HPLC system with a diode array detector supported
with HPLC Chromaster Driver for Waters® Empower™3
Software. Ten microliter of each sample were injected
using the auto-sampler. Size exclusion chromatography
was performed using a sephadexTM 200 10/300 GL col-
umn, with 0.5 mL/min elution rate using sterile PBS
(Sigma, sterile-filtered, isotonic, pH 7.2) as eluent.
Human cancer cell lines
Six cell lines from the NCI-60 cell panel representing six
distinct tumor types were used in this study: DU-145,
prostate carcinoma; MDA-MB-231, breast adenocarci-
noma; NCI-H23, lung adenocarcinoma; HCT-116, color-
ectal carcinoma; SK-MEL-28, malignant melanoma; and
OVCAR-3, ovarian adenocarcinoma. Cells, except DU-
145, were grown in RPMI-1640 medium (Mediatech)
containing 2mM L-glutamine, supplemented with 10%
FBS (Omega Scientific). DU-145 (human prostate cancer),
which was extensively used in this study, was grown in
EMEM cell culture medium (ATCC) containing 2mM L-
glutamine, supplemented with 10% fetal bovine serum
(FBS, Biological Industries), and maintained at 37 °C
under 5% CO2 in a humidified incubator. Cell lines were
maintained up to 10 passages.
Crystal Violet growth inhibition assay
Tumor cells (DU-145, MDA-MB-231, SK-MEL-28,
NCI-H23, HCT-116, and OVCAR-3) were seeded in 96-
well microtiter plates (5 × 103 cells per well; 90 μL per
well) 24 h before the addition of the assigned NPs. At the
time of drug treatment, stock solutions of compounds
were diluted to 10-fold the desired final test concentra-
tions with RPMI-1640 medium. Aliquots of 10 μL of these
diluted solutions were added to the appropriate microtiter
wells containing 90 μL of growth medium, resulting in the
required final drug concentrations (eight concentrations
per compound, ranging from 0.3 to 600 μM). The final
concentration of DMSO (the compound required DMSO
for solvation) in test culture was <1%. All cells were
incubated in the dark throughout the 24–72 h exposure
period and did not receive prolonged exposure to light.
Following 24–72 h of exposure at 37 °C, cell viability was
determined using the crystal violet assay (Promega/Sigma
Aldrich/Sigma Aldrich) according to the manufacturer’s
instructions. Absorbance was measured using a micro-
plate reader (Synergy 4; Biotek Instruments) at 595 nm.
Experiments were performed in triplicates and each dose-
response curve represents the mean of three or more
independent experiments. Spectrophotometric data were
analyzed by sigmoid dose-response, nonlinear regression
analysis; the IC50 values and associated SEM were calcu-
lated using GraphPad Prism 6 (GraphPad Software) or
with Microsoft excel software.
Flow cytometry analysis
DU-145 cells were seeded in 6-well plates (5 × 104 cells/
mL; 2.7 mL per well) 24 h before the addition of assigned
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compounds/albumin NPs. At the time of drug treatment,
stock solutions of compounds were diluted to 10-fold the
desired final test concentrations in EMEM medium. Ali-
quots of 300 μL of these diluted drug solutions were
added to the appropriate microtiter wells containing
2.7 mL of growth medium, resulting in the required final
drug concentrations. The final concentration of DMSO
(given that the compound required DMSO for solvation)
in test culture was <1%. All cells were incubated in the
dark throughout the 24–72 h exposure period and did not
receive prolonged exposure to light. Following 24–72 h of
exposure at 37 °C, cell apoptosis/cell cycle/mitochondrial
depolarization were determined with Annexin V-FITC kit
(Sigma Aldrich)/ MitoProbe™ DiOC2(3) Assay Kit (Life
Technologies, Rhenium, Jerusalem, Israel), respectively,
according to the manufacturer’s instructions. Samples
were taken for measurement using a BD LSR-II Analyzer
supported with BD FACSDiVaTM Software Version 6.1
for data analysis. Corrole fluorescence in binding analysis
was measured using appropriate filters for excitation
(405 nm, DAPI) and emission (<590 nm, Ds-RED).
Live cell imaging
DU-145 cells were seeded in 24-well plates containing a
glass optic bottom (5 × 104 cells/mL; 0.9 mL per well) 24 h
before the addition of the assigned NPs. At the time of
drug treatment, stock solutions of compounds were
diluted to 10-fold the desired final test concentrations in
EMEM medium. Aliquots of 100 μL of these diluted
solutions were added to the appropriate microtiter wells
containing 0.9 mL of medium, resulting in the required
final drug concentrations. MitoTracker Green (MTG) and
LysoTracker green (LTG) (Life Technologies, Rhenium,
Jerusalem, Israel) were optimized for concentrations,
incubation time and labeling, and added in accordance
with the manufacturer’s instructions. LTG was added
prior to NPs whereas MTG was added after the addition
of NPs and washed for co-localization analysis.
For the study using endocytosis inhibitors, DU-145 cells
were pre-incubated with chlorpromazine (20 µM), nysta-
tin (30 µM), chloroquine (100 µM), and indomethacin
(300 µM; Sigma Aldrich, St Louis, MO, USA) for 30min,
washed with PBS, followed by the 1-h exposure to 20 µM
of (2)Ga/HSA NPs at 37 °C. IC50 values and optimized
concentrations of the inhibitors were assessed in the DU-
145 cell line. The final concentration of DMSO (com-
pound required DMSO for solvation) in test culture was
<1%.
The interaction of (2)Ga/HSA NPs with the plasma
membrane were examined using HSA-FITC conjugates
are from Sigma (Sigma Aldrich, St Louis, MO, USA). (2)
Ga/HSA-FITC NPs were formulated in accordance with
previously detailed protocols. All cells were incubated in
the dark throughout the 4–24 h exposure period and did
not receive prolonged exposure to light until excitation by
the proper wavelengths. Following 4–24 h of exposure at
37 °C, cellular corrole uptake and organelle labeling was
determined using a ×20 objective and a LSM700 confocal
system supported with Zen software. Samples were exci-
ted at 488 nm for MTG, LTG and HSA-FITC detection
(3%, 5%, and 3%, respectively); and at 405 nm (10%) for (2)
Ga detection.
Western blot analysis
DU145 cells were seeded in a 6-well plates at a density
of 4 × 105 cells/well and allowed to attach and equilibrate
overnight. Cells were then pre-treated for 3 h with the
vehicle control, 50 µM Z-VAD-FMK or Necrostatin-1,
inhibitors of apoptosis or necroptosis, respectively. Fol-
lowing pretreatment, cells were incubated for 20 h with
(2)Ga/HSA NP (NPs; 5, 10, 15, or 20 µM), NPs (15 µM),
or camptothecin (CPT; 5 µM) without the removal of
inhibitors. Proteins were isolated from DU145 cells using
RIPA lysis and extraction buffer (Thermo Fisher, Wal-
tham, MA) containing cOmplete protease inhibitor
cocktail (MilliporeSigma, St. Louis, MO). The amount of
protein was quantified using the BCA Protein Assay Kit
(Thermo Fisher, Waltham, MA). Protein samples (30 μg)
were denatured in Laemmli sample buffer (Bio-rad, Her-
cules, CA), separated on 4–20% polyacrylamide gradient
gel (SDS-PAGE), and transferred onto PVDF membrane
using the Trans-Blot Turbo Transfer System (Bio-rad,
Hercules, CA). Membranes were probed for the proteins
of interest using the following antibodies (each at 1:1000):
caspase-3 (#9662), cleaved caspase-3 (#ab32042), PARP
(#9542), and β-actin (#4970). Peroxidase-conjugated sec-
ondary antibodies against rabbit was used at 1:1000 and
immunodetection was achieved using ECL Plus Western
Blotting Substrate (Pierce Thermo Fisher, Waltham, MA).
Immunoblots were analyzed digitally with a BioRad Che-
miDoc Imaging System and quantification was performed
using the ImageLab software (Bio-rad, Hercules, CA).
Live cell IN CELL analysis
Cells (DU-145) were seeded in 24-well microtiter plates
with a glass optic bottom (5 × 104 cells/mL; 0.9 mL per
well) 24 h before the addition of assigned NPs and com-
pounds. At the time of drug treatment, stock solutions of
the compounds were diluted to 10-fold the desired final
test concentrations in EMEM medium. Aliquots of 100 μL
of these diluted drug solutions were added to the appro-
priate microtiter wells containing 0.9 mL of medium,
resulting in the required final drug concentrations
(according to assigned concentration). Fluo-8 AM
(Abcam, Zotal LTD, Tel Aviv, Israel) and CellROX green
(Life Technologies, Rhenium, Jerusalem, Israel) were
added prior to drug treatment in accordance with the
manufacturer’s instructions and were optimized for
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concentrations, incubation time, and labeling results. The
final concentration of DMSO (the compound required
DMSO for solvation) in test culture was <1%. All cells
were incubated in the dark throughout the time of
exposure period and did not receive prolonged exposure
to light until excitation by the proper wavelengths. Fol-
lowing Fluo-8 AM and CellROX green incubation at 37 °C
for 30min, cells were washed with PBS and fresh medium
was added. Plates were taken for fluorescence microscopy
imaging using a ×20 (0.95 NA, WD 0.15 mm) objective
and a GE IN Cell Analyzer 2000 supported with an IN
Cell Miner software for data analysis and image man-
agements. (2)Ga was added at the assigned concentrations
at the moment of imaging (t= 0). For (2)Ga uptake
imaging and phototoxicity assays, cells were excited using
a CFP filter (430_24×) from a white LED light source and
emission was recorded using a CY3 filter (579_34×). For
both Fluo-8 AM and CellROX green detection, a FITC
filter for excitation (490_20×• 500_20×) and emission
(525_36m• 535_30m•) was used. Quantification of signals
was done using IN Cell software and Microsoft Excel
software.
NPs isolation protocol
Two hundred micromolar (2)Ga/HSA NPs were cen-
trifuged at 20,000×g for 30 min. The supernatant was
transferred to a new tube for two additional centrifuga-
tions and transfers. The pellet was resuspended with PBS,
pH 7.2, 500 µL and went through two additional cycles of
centrifugation and resuspension. After isolation protocols,
the concentration of the corrole in each sample (i.e.,
supernatant and pellet) was assessed using UV-Vis for
further in vitro assays.
Statistical analysis
Data were expressed as mean ± S.E.M and were com-
pared between experimental groups with the use of one-
way analysis of variance followed by Tukey’s post hoc test
unless otherwise specified (Analyze-it software for Win-
dows Excel, Leeds, UK). Probability values of p < 0.05
were considered to be statistically significant.
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